You are here: Contents > 2018-19 > Volume 27 Number 1 (2018-19) > CASE REPORTS > TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

Jan-Philipp Minol^1,3, Tobias Zeus², Alexander Blehm¹, Verena Veulemans² ¹Department of Cardiovascular Surgery, University Hospital, Düsseldorf, Germany ²Department of Cardiology, Pulmonology and Angiology, University Hospital, Düsseldorf, Germany ³Electronic correspondence: phil.minol@gmx.de
Osteogenesis imperfecta (OI) is a syndrome that is often associated with dysfunction of the aortic valve. Because of the resultant fragile vessels and impaired hemostasis, surgical therapy to treat OI is challenging. Previous reports have suggested that transcatheter aortic valve implantation (TAVI) might be a suitable treatment for this condition. To the best of the authors’ knowledge,	the present case is the first to describe a young patient who underwent successful TAVI to treat osteogenesis imperfecta. The proposal of transfemoral TAVI serving as first-line therapy for aortic valve stenosis in patients suffering from osteogenesis imperfect was confirmed. The Journal of Heart Valve Disease 2018;27:104-106
TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.

Select From:

TAVI as Therapy of Choice for Aortic Valve Disease in Osteogenesis Imperfecta

Purchase this Article

Search: